Delivery of bioactive molecules to mitochondria in vivo

By Robin A. J. Smith, C. M. Porteous, A. M. Gane, M. Murphy. Proceedings of the National Academy of Sciences of the United States of America, 2003

686 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Mitochondrial dysfunction and oxidative stress in metabolic disorders - A Step towards mitochondria based therapeutic strategies (2016, background): “damage induced by the excess of ROS in many pathogenic conditions [217,220,230].”
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. (2014, background): “An investigation indicated that the positively charged TPP could accumulate several hundred folds within mitochondria [299].”
Calcium, ATP, and ROS: a mitochondrial love-hate triangle. (2004, background): “Clearly, the development of mitochondrially targeted drugs is an important research direction, and a range of strategies have been exploited to target therapeutic agents to mitochondria (182, 196, 209, 210).”
Targeting an antioxidant to mitochondria decreases cardiac ischemia‐reperfusion injury (2005, background): “efficacy, delivery, and bioavailability (2, 3).”
Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. (2005, background): “and rapidly concentrated across the plasma membrane of viable cells by 5–10fold, and across the mitochondrial membrane by a further 20–50-fold [32].”